bempikibart (ADX-914)
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alopecia Areata
Conditions
Alopecia Areata
Trial Timeline
Sep 12, 2023 → Sep 1, 2026
NCT ID
NCT06018428About bempikibart (ADX-914)
bempikibart (ADX-914) is a phase 2 stage product being developed by Q32 Bio for Alopecia Areata. The current trial status is active. This product is registered under clinical trial identifier NCT06018428. Target conditions include Alopecia Areata.
What happened to similar drugs?
1 of 20 similar drugs in Alopecia Areata were approved
Approved (1) Terminated (0) Active (19)
Hype Score Breakdown
Clinical
12
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06018428 | Phase 2 | Active |
Competing Products
20 competing products in Alopecia Areata
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Baricitinib | Eli Lilly | Phase 2 | 42 |
| CTP-543 | Sun Pharmaceutical | Phase 2/3 | 42 |
| CTP-543 | Sun Pharmaceutical | Phase 3 | 40 |
| Deuruxolitinib + Placebo | Sun Pharmaceutical | Phase 3 | 47 |
| Baricitinib + Placebo | Eli Lilly | Phase 2/3 | 38 |
| Baricitinib 4 MG Oral Tablet | Eli Lilly | Approved | 47 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 47 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 40 |
| minoxidil | Johnson & Johnson | Phase 3 | 40 |
| 5% Minoxidil + 2% Minoxidil | Johnson & Johnson | Phase 3 | 40 |
| Minoxidil + vehicle of 5% Minoxidil topical foam | Johnson & Johnson | Phase 2 | 35 |
| 5% Minoxidil Topical Foam + Vehicle Topical Foam | Johnson & Johnson | Phase 3 | 40 |
| Upadacitinib + Upadacitinib Placebo | AbbVie | Phase 3 | 47 |
| Upadacitinib + Placebo | AbbVie | Phase 3 | 47 |
| Secukinumab + Placebo | Novartis | Phase 2 | 27 |
| Daxdilimab | Amgen | Phase 2 | 35 |
| Ritlecitinib | Pfizer | Pre-clinical | 30 |
| LITFULO | Pfizer | Pre-clinical | 30 |
| Ritlecitinib | Pfizer | Pre-clinical | 33 |
| Ritlecitinib higher dose + Ritlecitinib lower dose + Placebo | Pfizer | Phase 3 | 47 |